Could metformin be used as a treatment for preeclampsia
Abdel-Aleem, H., Shamash, A., Abd El-Azeem, H., Makhlouf, A., Shaaban, O. (2018). Could metformin be used as a treatment for preeclampsia. EKB Journal Management System, 3(1), 37-42. doi: 10.4103/JCMRP.JCMRP_45_17
Hany Abdel-Aleem; Ayman H. Shamash; Hanan G. Abd El-Azeem; Alaa M. Makhlouf; Omar M. Shaaban. "Could metformin be used as a treatment for preeclampsia". EKB Journal Management System, 3, 1, 2018, 37-42. doi: 10.4103/JCMRP.JCMRP_45_17
Abdel-Aleem, H., Shamash, A., Abd El-Azeem, H., Makhlouf, A., Shaaban, O. (2018). 'Could metformin be used as a treatment for preeclampsia', EKB Journal Management System, 3(1), pp. 37-42. doi: 10.4103/JCMRP.JCMRP_45_17
Abdel-Aleem, H., Shamash, A., Abd El-Azeem, H., Makhlouf, A., Shaaban, O. Could metformin be used as a treatment for preeclampsia. EKB Journal Management System, 2018; 3(1): 37-42. doi: 10.4103/JCMRP.JCMRP_45_17

Could metformin be used as a treatment for preeclampsia

Journal of Current Medical Research and Practice
Volume 3, Issue 1, January 2018, Page 37-42  XML PDF (267.59 K)
DOI: 10.4103/JCMRP.JCMRP_45_17
View on SCiNiTO View on SCiNiTO
Authors
Hany Abdel-Aleem; Ayman H. Shamash; Hanan G. Abd El-Azeem; Alaa M. Makhlouf; Omar M. Shaaban
Abstract
Objective
To test the effect of metformin on serum level of antiangiogenic factors, soluble endoglin (sEng) and soluble fms-like tyrosine kinase-1 (sFLT-1), in patients with preeclampsia (PE).
Patients and methods
A controlled before and after prospective study was conducted on 40 patients with nonsevere PE conducted in a tertiary hospital setting. At admission, clinical and laboratory investigations had been done. Metformin tablets (500 mg three times daily) with meals were given from the time of study admission till delivery or termination of pregnancy. Serum level of sEng and sFLT-1 were measured before and 1 week after metformin treatment. Outcome of delivery had been obtained.
Results
One week after metformin treatment, there was a statistically significant reduction in maternal sEng and sFLT-1, with a mean difference of −448.86 ± 238.48 and −397.72 ± 125.52 pg/ml, respectively. In addition, there were significant reductions in both systolic blood pressure from 147 ± 12.4 to 131 ± 10.6 mmHg and diastolic blood pressure from 92 ± 7 to 85 ± 8.2 mmHg 1 week after metformin use. Five (12.5%) cases progressed to severe PE.
Conclusion
Metformin use for 1 week reduces the antiangiogenic biomarkers sEng and sFLT-1, and it could have a role in the treatment of PE.
Keywords
Metformin; preeclampsia; serum endoglin; tyrosine kinase-1
Statistics
Article View: 33
PDF Download: 23